Shanghai Biopharmaceutical Industry Innovation Alliance Was Established
Feb 07, 2021
Leave a message
Under the guidance of the Shanghai Municipal Commission of Economy and Information Technology, Shanghai Biopharmaceutical Industry Innovation Alliance was established by 33 units voluntarily joined by material and equipment manufacturers in the pharmaceutical industry chain, such as Junshi Biosciences, Mabwell, Henlius, East China University of Science and Technology, and BioEngine.
On February 5, 2021, the inaugural meeting of the Innovation Alliance was successfully held at Shanghai Huibo Center, and the constitution and organization list of the Alliance was formally adopted. Chief Engineer Liu Ping of the Municipal Commission of Economic and Information Technology and representatives of alliance units jointly inaugurated the establishment of the alliance.

At the inaugural meeting, Chief Engineer Liu Ping said: The members of the alliance are all cutting-edge units in the biopharmaceutical industry, which are the driving force for the whole industry to move upward. The establishment of the alliance implements the innovation-driven development strategy and will accelerate the construction of Shanghai as a scientific and technological innovation center with global influence.
As a representative of the member units, Prof. Tan Wensong, the chairman of BioEngine, an expert in animal cell culture process and bioreactor engineering in China, delivered a speech on the large-scale culture technology of animal cells, discussing the application of animal cell culture technology in biopharmaceutical field and the opportunities and challenges faced in the future.


In the future, BioEngine will do its best to promote the construction of independent innovation capacity and the research and development of key technologies together with the alliance, accelerate the localization of key raw materials and bioreactor equipment, build China's independent standardization system of culture medium raw materials, and promote the sustainable development of biopharmaceutical industry.


